Takeda's US supply deal with Fresenius set to boost early uptake of Omontys
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceuticals America's supply tie-up with Fresenius Medical Care North America for Omontys (peginesatide) should allow the long-acting erythropoiesis-stimulating agent (ESA) to penetrate early into one of the main dialysis networks in the US.